Visceral leishmaniasis (VL) is a protozoan parasitic disease, fatal in the absence of treatment. Although drug treatment exists for VL (17, 42) , alternative approaches for the control of this disease (vector control, immunotherapeutic, chemotherapeutic, and vaccine) are still needed (8, 45) . Vaccine studies of VL have been less extensive (6, 11-13, 22, 36) , and the level of protection found is generally poorer than those found for murine cutaneous leishmaniasis. However, studies utilizing a murine intradermal infection model of VL indicate that this is, in part, due to the animal model employed (1) . Immunological studies of the mechanisms of pathogenesis as well as immunotherapeutic studies of VL indicate tissue site-specific mechanisms (for the spleen, liver, and lymph node) (9, 10, 41) . Consequently, one of the challenges in the development of a vaccine against VL is the induction of protection at multiple and distinct tissue sites.
The LACK antigen (Leishmania analogue of the receptors of activated C kinase) (36 kDa) is highly conserved among Leishmania species and expressed by both the promastigote and amastigote forms of the parasite (25) . Studies indicate that DNA coding for the LACK antigen provides protection against Leishmania major. However, a LACK DNA vaccine failed to protect against L. mexicana (7). Further, a LACK DNA vaccine, although highly immunogenic, failed to protect against murine VL in either intradermal or intravenous infection (23) , suggesting that LACK may not be a useful antigen for a general DNA-based vaccine against leishmaniasis.
However, the antigen delivery system can be a critical component in determining antigenic efficacy. Vaccinia virus vectors have been shown to be a good antigen delivery system for the control of infectious diseases in animal model studies (24) . A heterologous prime-boost regimen using DNA and vaccinia viruses expressing the LACK antigen has been shown to be highly immunogenic and protective against murine L. major infection (15, 20, 44) . A heterologous prime-boost regimen using DNA and the replication-competent Western Reserve (WR) strain of vaccinia virus expressing the LACK antigen was recently explored in canine VL (37) . However, the immune response in the canine model is known to significantly differ from those in the murine and human hosts of leishmaniae in terms of their regulation by interleukin-13 (IL-13), IL-12, and IL-10 (34, 35, 38, 39) . Previous leishmaniasis vaccine studies, however, have demonstrated that the murine model can be predictive for vaccine outcomes in nonhuman-primate models (3, 5, 21) . Therefore, in the current study, the potential of a prime-boost regimen using DNA-vaccinia virus was further explored using the murine intradermal model for VL. In order to assess the potential use of this vaccination regimen against murine VL, the efficacies of priming were examined using an L. infantum DNA-LACK construct (previously employed for vaccine studies against cutaneous leishmaniasis caused by L. major [44] ) and the highly attenuated modified vaccinia virus Ankara (MVA) strain as well as the replication-competent WR strain, given the abilities of these viruses to induce both strong Th1 and CD8
ϩ T-cell responses (2, 14, 43) . BALB/c mice (4 to 6 weeks of age) were vaccinated intradermally with 100 g of DNA encoding the LACK antigen (DNAp36) and then boosted 2 weeks later intraperitoneally with 1 ϫ 10 7 or 5 ϫ 10 7 PFU of either recombinant Western Reserve-wild-type (WR-LACK or WRp36) or Ankara-MVA (MVA-LACK or MVAp36) vaccinia viruses expressing the LACK antigen. Three and one-half weeks after boosting, mice were infected intradermally in the ear pinnae using 10 7 metacyclic promastigotes of L. infantum, as previously described (1) . One month after infection, the parasite burdens were evaluated by limiting dilution analysis in vaccinated and con-trol groups of mice (1) . This evaluation of protection in the spleen, the liver, and the draining lymph node demonstrated that the mice receiving a prime-boost vaccination using the LACK (p36) antigen were significantly protected against infection (Fig. 1) . The levels of protection at each tissue site were comparable among the various vaccinated groups of mice and did not statistically differ between mice receiving the WRp36 or the MVAp36 virus. However, the level of protection did vary with the target organ site, with the highest levels of protection achieved in the draining lymph node (Fig. 1C) . The level of protection in the draining lymph node was evidenced by a 144-to 244-fold reduction in the parasite burdens in comparison to those of control mice. Lower levels of protection were achieved when the parasite burdens were evaluated in the spleen and the liver. These results ranged from 6-to 9-fold reductions in parasite burdens in the liver and 9-to 30-fold reductions in the spleen. In the spleen, a slight protective effect was also observed for the mice receiving control DNA and vaccinia virus (WR-Luc), which may be due to the low gamma interferon (IFN-␥) response observed for these mice (Fig. 2) . However, in other vaccine experiments employing WR-Luc (10 7 PFU) (44; data not shown) an IFN-␥ response and a reduction of the splenic parasite burden were not consistently observed, nor were reductions in parasite burdens observed in the livers and lymph nodes of the WR-Luc-vaccinated mice (Fig. 1) . However, the differences between the parasite burdens observed for the WR-Luc-vaccinated mice and those for mice receiving WR-LACK or MVA-LACK were significant (P Ͻ 0.02 to 0.05) (Fig. 1A) , demonstrating a LACK antigen-specific effect.
IFN-␥ and tumor necrosis factor alpha/lymphotoxin (TNF-␣/LT) have been found to be involved in resistance to infection in murine VL (27, 29, 30, 46) , while IL-10 correlates with susceptibility (26, 33) . The levels of IFN-␥, IL-10, and TNF-␣/LT produced by spleen cells of vaccinated and nonvaccinated mice in response to LACK antigen were evaluated before infection and at 1 month after infection (Fig. 2) . Before infection, mice receiving 10 7 WRp36 or 5 ϫ 10 7 MVAp36 PFU appeared to produce somewhat higher levels of IFN-␥ (100 to 113 ng/ml) than mice boosted with either 5 ϫ 10 7 WRp36 or 10 7 MVAp36 PFU (55 to 67 ng/ml) ( Fig. 2A) . As shown in Fig.  2B , enzyme-linked immunospot analyses (44) indicated that the number of IFN-␥-secreting cells correlated with the levels of IFN-␥ found by enzyme-linked immunosorbent assay (ELISA), with the frequency of IFN-␥-producing cells ranging from 380 to 640/10 6 spleen cells. In addition, significant levels of TNF-␣/LT (58 and 134 pg/ml) were observed for mice boosted with recombinant wild-type WRp36, while lower levels of TNF-␣/LT were produced in response to LACK antigen by mice receiving MVAp36 (27 pg/ml and 8 pg/ml, respectively). These differences in the levels of induction of TNF-␣ may reflect, in part, the different abilities of WR and attenuated MVA vaccinia viruses to induce an inflammatory response and NF-B activation, which result in distinct cytokine profiles. MVA has been shown to enhance NF-B activation, while WR appears to inhibit it (18, 32, 40) .
The amounts of LACK-specific IL-10 produced by splenocytes before challenge varied from 0.1 ng/ml in mice boosted with 5 ϫ 10 7 WRp36 PFU to 0.7 ng/ml in those receiving 10 7
WRp36 or MVAp36 PFU (Fig. 2D) .
The cytokine responses at 1 month postinfection paralleled but were somewhat higher than those found prior to infection. IFN-␥ levels ranged from 20 ng/ml in mice receiving 5 ϫ 10 7 WRp36 PFU to 204 ng/ml in those boosted with 5 ϫ 10 7 MVAp36 PFU. The levels of TNF-␣/LT in response to LACK antigen stimulation in vaccinated mice ranged from 64 pg/ml in mice boosted with 10 7 MVAp36 PFU to 120 pg/ml in the group boosted with 5 ϫ 10 7 WRp36 PFU. Significant levels of IL-10 (0.04 ng/ml to 0.54 ng/ml) were also produced in response to LACK antigen at 1 month postinfection. Both the level of IFN-␥ and the IFN-␥/IL-10 ratio found at 1 month postinfection appeared to correlate with the protection levels found (Table 1) .
Both IFN-␥ and TNF-␣ are implicated in the macrophage killing of intracellular L. donovani, through the up-regulation of inducible NO synthase (iNOS) and production of nitrite oxide (28) . Nitric oxide has been demonstrated to be critical for the leishmanicidal activity of murine macrophages (4, 16, on January 20, 2018 by guest http://iai.asm.org/ 19) and also has been shown to enhance, at low levels, a Th1 response (31) . However, IL-10 is known to down-regulate macrophage NO production (26) . To further determine the ongoing immune response dynamics in the vaccinated versus control mice, the induction of NO/nitrite at 1 month postchallenge was examined. Significant amounts of this antimicrobial agent were observed and ranged from 6 to 7 M in the vaccinated mice, with control group NO/nitrite levels ranging from 0.6 M to 1 M. Therefore, the vaccinated mice, consistent with the findings for levels of IFN-␥ ( Fig. 2 ; Table 1 ), had higher levels of nitric oxide induction and potential leishmanicidal activity. These results were consistent with the protection found in the LACK-DNA-LACK-WR-or MVA-vaccinated mice.
In conclusion, this study demonstrated that a heterologous prime-boost regimen using DNA and vaccinia virus, both expressing the same antigen, LACK, is highly immunogenic and confers protection against murine L. infantum infection. Notably, the highly attenuated MVA and the replication-competent WR strain vaccinia viruses achieved comparable levels of protection. This heterologous prime-boost approach resulted in higher levels of IFN-␥ (up to 200 ng/ml) than those reported for DNA-DNA vaccination (6 to 12 ng/ml) (23), where protection was not achieved. This observation prompts a question on the biologically effective amount of IFN-␥ required to induce protection against VL. Although additional effector mechanisms may be involved, these results suggest that higher levels of IFN-␥ may be required for protection against visceral disease than are needed against cutaneous leishmaniasis. Future studies will explore the use of this vaccine approach for a composite/multicomponent strategy against visceral leishmaniasis. 
